BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Spero Therapeutics (SPRO)Spero TherapeuticsFinancing

Financing supports Phase 2 development of SP001, Spero's first immunology drug candidate, in-licensed from Innovent Biologics

Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside

Spero updates its...

Related news

ANTXAN2 Therapeutics2026-03-09 11:00 EST

AN2 Therapeutics Announces $40 Million Private Placement Financing

VIRIVirios Therapeutics2026-01-12 13:30 EST

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IMNNImunon2026-06-04 12:00 EST

IMUNON Announces Up to $10 Million Cash Financing

IMNNImunon2025-12-30 13:30 EST

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

COCPCocrystal Pharma2026-08-03 11:00 EST

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MBRXMoleculin Biotech, Inc.2026-07-31 14:12 EST

Moleculin Announces Pricing of $9.3 Million Public Offering

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Stock data

Close
1.19 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States